Vertex Pharmaceuticals (VRTX) is a biotechnology company in the Health Care sector. Listed on the NASDAQ, Vertex Pharmaceuticals is a component of the S&P 500 index. As of 2026-06-10, the stock is trading at $435.71.
Key Metrics & Risk
Based on 5-year historical data from Yahoo Finance (daily returns, annualized using 252 trading days).
| Metric | Value |
|---|---|
| Latest Price | $435.71 |
| Latest Date | 2026-06-10 |
| Expected Return (Annualized) | 20.50% |
| Risk / Std Dev (Annualized) | 28.53% |
| Sharpe Ratio (rf=4.5%) | 0.56 |
S&P 500 Context
- Sector: Health Care
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Index: S&P 500 Component
Risk/Return Profile
The stock shows an annualized expected return of 20.50% with an annualized volatility of 28.53%. The Sharpe ratio of 0.56 (assuming 4.5% risk-free rate) indicates moderate risk-adjusted returns relative to the risk-free rate.
Modern Portfolio Theory Positioning
This stock is plotted on the S&P 500 Modern Portfolio Theory chart which visualizes the risk/return trade-off across all S&P 500 components. The chart uses Sharpe ratio as the color dimension, allowing quick identification of stocks with superior risk-adjusted performance.
Fundamentals
| Metric | Value |
|---|---|
| Market Cap | 110.59B |
| Enterprise Value | 105.33B |
| Trailing P/E | 25.84 |
| Forward P/E | 20.29 |
| Price to Book | 5.72 |
| Price to Sales | 9.05 |
| EV/Revenue | 8.62 |
| EV/EBITDA | 21.14 |
| Profitability | | | Profit Margin | 35.51% | | Operating Margin | 38.13% | | ROE | 24.2% | | ROA | 12.14% |
| Growth | | | Revenue Growth | 7.8% | | Earnings Growth | 61.4% |
| Financial Health | | | Total Revenue | 12.22B | | Total Debt | 1.99B | | Total Cash | 7.25B | | Free Cash Flow | 2.78B | | Operating Cash Flow | 4.24B |
| Price & Technical | | | 52W High | $507.92$ | | 52W Low | $362.5$ | | 50-Day Avg | $436.98$ | | 200-Day Avg | $437.66$ | | Beta | 0.31 | | Shares Outstanding | 0.25B | | Float Shares | 0.25B | | Insider Holdings | 0.2% | | Institutional Holdings | 98.02% | | Short Ratio | 3.46 | | Short % of Float | 2.0% |
| Analyst Targets | | | Target High | $641.0$ | | Target Low | $330.0$ | | Target Mean | $548.69$ | | Target Median | $555.0$ | | # of Analysts | 29 | | Recommendation | buy |
Disclaimer
This analysis is for educational purposes only and does not constitute financial advice. Past performance is not indicative of future results. Always conduct your own research or consult a qualified financial advisor before making investment decisions.